Allergan PLC (NYSE:AGN) To Acquire Rights To Migraine Drugs From Merck & Co., Inc. (NYSE:MRK)

Earlier this week, Allergan PLC (NYSE:AGN) revealed plans to acquire exclusive rights to new migraine drugs from Merck & Co., Inc. (NYSE:MRK). The company announced that the two had closed a $250 million deal for the drugs, and the payment will be on an upfront basis. Merck might also benefit from royalty and milestone payments […]

GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) Shifts CEO Justin Gover To U.S.

In a bid to strengthen the company’s presence in North America, GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) has shifted CEO Justin Gover to the U.S. office. GW Pharmaceuticals is all set to enter the final stages and get the U.S. Food and Drug Administration (FDA) approval for an epilepsy treatment using cannabis. The company has also […]

Actavis plc (NYSE:ACT) Keeps Its Phase Iii Promise With Molecular Partners’ Eye Drug

Actavis plc (NYSE:ACT) is on track with maintaining its promise to Allergan, Inc. (NYSE:AGN) through the upcoming introduction of phase III trials for abicipar. The drug is licensed by Sweden-based Molecular Partners. The drug is the first of the projects that have a direct influence on the $66 million merger. Ambicipar is a promising drug […]

Allergan, Inc. (NYSE:AGN) Issues A Statement regarding Correspondence With Valeant Pharmaceuticals Intl Inc(NYSE:VRX)

Boston, MA 09/26/2014 (wallstreetpr) – According to reports, Allergan, Inc. (NYSE:AGN) has issued a statement consisting important information about its recent correspondence with Valeant Pharmaceuticals Intl Inc (NYSE:VRX). The statement was published by VRX sometime back. Management Call: Board of Directors of Allergan, Inc. (NYSE:AGN) is completely aware from the ongoing situation with VRX and its […]

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) Strengthens Itself In Battle To Acquire Allergan, Inc. (NYSE:AGN)

Boston, MA 09/25/2014 (wallstreetpr) – Valeant Pharmaceuticals Intl Inc (NYSE:VRX) yesterday said that its revenue for Q3, 2014 will be stronger than anticipated. The company pushed Allegan harder to accept its offer on this pretext. Better-Than-Expected Results Formerly known as Biovail Corporation, Valeant, said it expects the following quarter’s revenue figures to be higher than those […]

Wall Street Highlight: The Dow Chemical (DOW), Allergan (AGN), Chesapeake Energy (CHK)

Boston, MA 09/24/2014 (wallstreetpr) – The Dow Chemical Company (NYSE:DOW) will be responsible for the reduction of greenhouse gas emissions at the upcoming 2016 Olympic Games in Brazil. The company was selected as the official partner for the environmental sustainability program during the games. The program seeks to lower the impact of the games on […]

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) Acquisition Likely To Aid Allergan, Inc. (NYSE:AGN) Avert Ackman’s Proposal

Boston, MA 09/24/2014 (wallstreetpr) – The talks about a merger between Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) and Botox-maker, Allergan, Inc. (NYSE:AGN) have infuriated activist investor William Ackman, who has threatened to sue the later, if the deal finalizes. Take-Over Battle Mr. Ackman is supporting and pushing the idea of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) acquiring Allergan. However, […]

Support Grows For Special Meeting Of Allergan, Inc. (NYSE:AGN) Shareholders

Boston, MA 09/12/2014 (wallstreetpr) – More investors in Allergan, Inc. (NYSE:AGN) continue to show their support for a special shareholder meeting, The Wall Street Journal stated in an article. The meeting is being sought by William Ackman’s Pershing Square Capital Management LP and Valeant Pharmaceuticals Intl Inc (NYSE:VRX). The two are seeking to take over […]

Allergan, Inc. (NYSE:AGN) And Valeant Pharmaceuticals Intl Inc (NYSE:VRX) Fight Taking A Legal Shape As Latter Files A Lawsuit

Boston, MA 08/25/2014 (wallstreetpr) – In order to put the acquisition of Allergan, Inc. (NYSE:AGN) deal in the fastest gear, Valeant Pharmaceuticals Intl Inc (NYSE:VRX) as well as William Ackman (Pershing Square Capital Management LP activist), are taking the lawsuit path. In the hostile $53 billion acquisition bid for Allergan, the two are looking forward to […]

Are Investors of Allergan, Inc. (NYSE:AGN) Taken For a Ride By Hedge Fund? Are Hedge Funds In Collusion Course On Allergan, Inc. (NYSE:AGN) Shares?

Boston, MA 08/15/2014 (wallstreetpr) – Are head fund companies made a big money out of Allergan, Inc. (NYSE:AGN)’s potential bid to be sold or a takeover target company? If so, are the investors taken for a ride? If reports are to be believed, the regulator, Securities Exchange Commission or the SEC, seemed to have seized […]

Allergan, Inc. (NYSE:AGN) To Meet FDA Over Rejected Drug

Boston, MA 07/01/2014 (wallstreetpr) – Allergan, Inc. (NYSE:AGN) plans to meet the Food and Drug Administration to discuss the way forward for its rejected treatment known as Levadex or Semprana. The drug is being offered as a migraine inhaler. However, the regulator refused to approve the treatment citing a problem with the delivery device of […]

Morgan Stanley (NYSE:MS) Pitched Its Defense Services To Allergan

Boston, MA 06/19/2014 (wallstreetpr) – Morgan Stanley (NYSE:MS) is the advice-giver to the Canada based pharmaceutical company, Valeant Pharmaceuticals Intl Inc (NYSE:VRX) in its $53 billion bid for Allergan, Inc. (NYSE:AGN). Morgan Stanley, the global financial service firm initially attempted to get appointed by Allergan. According to Allergan, Morgan Stanley is the unwanted bidder in […]

Allergan, Inc. (NYSE:AGN) Loses Latisse Eyelash Ruling; Rejects Valeant Pharmaceuticals Intl Inc (NYSE:VRX) Offer

Boston, MA 06/11/2014 (wallstreetpr) – Allergan, Inc. (NYSE:AGN), the Botox wrinkle therapy maker, lost a ruling in the appeals court which will cause generic versions of the company’s Latisse eyelash medicine enter the marketplace. Ruling Rejected Allergan, Inc. (NYSE:AGN) and Duke University owned two patents on its drug Latisse but as per the website posting, […]

Allergan, Inc. (NYSE:AGN) Under Pressure After William Ackman Seeks Removal Of Allergan Directors

Boston, MA 06/05/2014 (wallstreetpr) – Allergan, Inc. (NYSE:AGN) came under pressure after William Ackman, the activist investor and Valeant Pharmaceuticals Intl Inc (NYSE:VRX) paved way for $52.7 billion takeover on June 2, 2014. The Act of Informal Shareholder Referendum With this, the plans of informal shareholder referendum were also dropped. It was said that the […]

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) Raises Bid To $53 Billion To Buy Allergan, Inc. (NYSE:AGN)

Boston, MA 06/02/2014 (wallstreetpr) – Valeant Pharmaceuticals Intl Inc (NYSE:VRX) increased its offer to acquire Allergan, Inc. (NYSE:AGN) for the second time in the week. Second Raise In A Week The Canada based drug maker said on Friday that it is agreeable to offer $72 and in addition a part of its stock for each […]